Pfizer has decided to stop the Phase III trial of figitumumab, its drug candidate for lung cancer, after an analysis found that combining the drug with paclitaxel and carboplatin would be unlikely to satisfy the study's primary endpoint. "While these findings are disappointing, Pfizer is committed to using information gained from this study to refine the design of future trials of figitumumab in non-small cell lung cancer," a Pfizer executive said.

Full Story:

Related Summaries